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O
ne of most intriguing discoveries in biology in
recent years is unquestionably the identiﬁca-
tion of the family of small, noncoding RNAs
known as microRNAs (miRNAs). Originally de-
scribed in worms (1), miRNAs are now known to be
virtually ubiquitous among vertebrates, including humans.
Over 400 genes encoding miRNAs are dispersed through-
out the human genome, many of them unexpectedly
located within the borders of conventional, protein-coding
genes (2). miRNA genes are transcribed primarily by RNA
polymerase II into long precursor molecules that are
processed via the RNase III enzymes Drosha and Dicer
into the mature, 22-nucleotide miRNA (3,4).
Functional studies are beginning to reveal the involve-
ment of miRNAs in a remarkable array of key cellular
activities including differentiation, proliferation, and met-
abolic integration (5). Each miRNA targets multiple mRNA
species through recognition of complementary sequences,
typically located at multiple sites within the 3 untrans-
lated region. This results in reduction in the level of the
corresponding protein, either through destabilization of
the mRNA or inhibition of translation (3). The effects of
each such interaction may be subtle, complicating the
process of dissecting out these effects. Nevertheless, it is
becoming abundantly clear that the miRNAs have a pro-
found effect on controlling and integrating programs of
gene expression. For example, miRNAs can act both
upstream and downstream of key cellular transcription
factors (6), thereby exerting broadly pleiotropic effects.
Furthermore, evidence is now accumulating that links
miRNA to diseases including cancer, neurological dis-
orders, and a variety of developmental defects (7).
Although miRNAs are notably absent from the rapidly
expanding list of genes associated with type 2 diabetes
risk (8), a link between miRNAs and diabetes now seems
increasingly likely. What is the evidence for such a
connection?
In 2004, Poy et al. (9) identiﬁed several miRNAs ex-
pressed selectively in pancreatic endocrine cell lines:
among these was miR-375, overexpression of which re-
sulted in suppressed glucose-stimulated insulin secretion
and whose inhibition enhanced insulin secretion. One of
the targets of miR-375 was identiﬁed as myotrophin, a protein
implicated in exocytosis. Indeed, inhibition of myotrophin
production mimicked the effects of miR-375 on insulin
secretion. These results establish miR-375 as a potentially
important modulator of -cell function, but what are the
other targets of miR-375? A study by El Ouaamari et al.
(10) in this issue of Diabetes presents a tantalizing new
candidate: PDK1 (3-phosphoinositide–dependent protein
kinase 1). Well known as an important component of the
PI3K/protein kinase B signal cascade that plays a key role
in mediating action of insulin on cell growth and develop-
ment (11), the central role of PDK1 in -cells was demon-
strated recently through ablation of PDK1 in -cells, which
leads to diabetes concomitant with reduced -cell mass
(12). Using computational algorithms, El Ouaamari et al.
identiﬁed a single miR-375 binding site in the PDK1 3
untranslated region. Indeed, overexpression of miR-375
in -cell lines led to reduced levels of PDK1 protein,
accompanied by reduced downstream signaling, includ-
ing protein kinase B and glycogen synthase kinase-3
phosphorylation. In accord with the known actions of
the PI3K signaling pathway, miR-375 led to reduced
-cell number and viability, in parallel with reduced
potency of glucose in mediating increases in insulin
mRNA. Conversely, inhibition of miR-375 expression led
to increased PDK1 levels, as well as elevated glucose-
dependent insulin mRNA and -cell proliferation. El
Ouaamari et al. report that glucose is a potential nega-
tive modulator of miR-375, and consistent with this,
glucose leads to substantial increase in PDK1 protein
levels. Finally, glucose is shown to reduce miR-375 in
isolated rat islets, and miR-375 levels appear to be
reduced in islets of the diabetic Goto-Kakizaki (GK) rat.
The study of El Ouaamari et al. represents a substantial
advance because it provides a plausible connection be-
tween miRNAs and a critical -cell signaling pathway,
linked to cell proliferation and apoptosis. Yet, there are
signiﬁcant caveats: e.g., much of the evidence presented
by El Ouaamari et al. is based on experiments involving
substantial overexpression (500 fold) of miR-375 in
-cell lines. It will therefore be essential to conﬁrm these
results in a more physiological setting, ideally in mice
bearing selective ablation of the miR-375 gene in -cells. In
fact, German and colleagues (13) recently generated
mouse models in which miRNA generation is globally
blocked through deletion of a conditional Dicer allele.
When Dicer was deleted at an early stage of pancreas
development (using the Pdx-1 promoter), serious develop-
mental defects were observed in all pancreatic cell types,
consistent with a critical role for miRNAs during pancreas
development. When Dicer was deleted later in develop-
ment (using the insulin promoter), little effect was seen
either on pancreas morphology or on -cell maintenance,
which is perhaps surprising in view of the fact that these
-cells are expected to lack all miRNAs. Although these
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during development (14), they leave open the precise role
in the adult islet and emphasize the need for detailed
studies on mice lacking miR-375. Unpublished results
(cited in ref. 15), indicate that mice lacking miR-375 are
hyperglycemic, perhaps as a result of reduced -cell mass.
Whether this is a result of a developmental defect or an
impairment in the function of mature -cells remains to be
established.
How is miR-375 expression controlled ? El Ouaamari et
al. propose glucose as one factor, an intriguing idea given
the central role of glucose in -cell function and the notion
that glucose may play an important role in driving the
compensatory -cell hyperplasia characteristic of the in-
sulin-resistant state (16). Thus, miR-375 may be involved in
mediating the -cell proliferation observed in pregnancy
and obesity. Additional regulators of miR-375 expression
are suggested by the work of Keller et al. (17), who
recently identiﬁed conserved sites near the miR-375 gene
as potential targets of the critical pancreas transcription
factors Pdx-1 and NeuroD1, hinting that miR-375 may be
an important player in the network of interacting tran-
scription factors that control pancreas development and
maintenance (18).
Clearly, the study of El Ouaamari et al. represents one
piece of a large and complex emerging puzzle. It will be
important to identify additional targets of miR-375 and
other miRNAs expressed in -cells (19,20) and to establish
how they function in developing and mature cells. The
interactions of miRNAs with transcription factor networks
are likely to provide valuable clues. Finally, fueled by the
links between miRNAs and human disease, powerful tools
are being developed to improve detection and manipula-
tion of miRNAs (7). Though a “smoking gun” directly
linking miRNAs to diabetes has yet to be uncovered, it
seems likely that further research in this area may lead to
signiﬁcant new diagnostic and therapeutic approaches to
diabetes.
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